Tremelimumab plus Durvalumab in Unresectable Hepatocellular CarcinomaGhassan K. Abou‐Alfa, Bruno Sangro, Lorenza Rimassa et al.|NEJM Evidence|2022Cited by 1.4k
Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.Ghassan K. Abou‐Alfa, Bruno Sangro, Stephen L. Chan et al.|Journal of Clinical Oncology|2022Cited by 398
The PI3K inhibitor copanlisib synergizes with sorafenib to induce cell death in hepatocellular carcinomaLiangtao Ye, Enrico N. De Toni|Cell Death Discovery|2019Cited by 60
Combined Hepatocellular-Cholangiocarcinoma: Biology, Diagnosis, and ManagementLiangtao Ye, Florian P. Reiter, Julia S. Schneider et al.|Liver Cancer|2023Cited by 44
Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cellsFlorian P. Reiter, Enrico N. De Toni|Cellular Oncology|2019Cited by 24